Baxter Q4 adj EPS $0.58 beats guidance; Q4 sales $2.75B (+2% CC)

BAXTER INTERNATIONAL INC

2024-FY EPS reported -$1.27 revenue$10,636,000,000

Q4 sales from continuing ops $2.75B, up 1% reported / 2% constant currency, exceeding guidance.
GAAP diluted EPS loss ($0.95); adjusted EPS $0.58, ahead of company's guidance range.
Full-year 2024 sales $10.64B (+3% reported & CC); adjusted EPS $1.89, exceeded guidance.
Sale of Kidney Care business completed, streamlining Baxter for next stage of growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.